Page 218 - Read Online
P. 218

Raja. Vessel Plus 2019;3:23  I  http://dx.doi.org/10.20517/2574-1209.2019.05                                                                Page 5 of 11





                                                                                  RITA
                                    LITA       RITA                                                    LITA
                                                                        LITA


                                                                                  RA

                                        RA
                                                 RA






               Figure 5. Composite configurations of radial artery. A: Radial artery (RA) Y or T graft from the in situ left internal mammary artery (LITA)
               anastomosed to the circumflex marginal branches and distal branches of right coronary artery; B: RA Y or T graft from the in situ right
               internal thoracic artery (RITA) anastomosed to the distal branches of right coronary artery; C: Extension of RITA with RA. (Figure courtesy
               Marcie Bunalade)

               skeletonization and can be lengthened with recycled LIMA or radial artery [Figure 5]. The RIMA should
               not be anastomosed to the main RCA because of the possibility of competitive flow due to size disparity
                                                                [12]
               and ultimately evolution of progressive disease at the crux .
               Right gastroepiploic artery
               The right gastroepiploic artery can be combined with in situ RIMA to the LAD and LIMA to the obtuse
               marginal. Right gastroepiploic artery is particularly useful for grafting an occluded dominant ungrafted
               RCA or one with a failed graft in the presence of patent grafts to the left side. Grafting of the PDA can be
               achieved off-pump through a reasonably small incision via the lower sternum.


               OUTCOMES
               Perioperative outcomes
               The perioperative outcomes of TAR are similar to those of conventional CABG. Majority of the
               studies report 1% mortality and a 1%-3% rate for stroke, intra-aortic balloon pump use and myocardial
               infarction [18-21] . There is increasing acceptance that TAR should be offered only to younger patients (usually
               now perceived as less than 70 years old), predominantly with preserved ventricular function and absence
               of significant co-morbidity, as they are more likely to benefit from the superior long-term patency of the
                           [12]
               arterial grafts . However, TAR in combination with off-pump CABG can also be offered to the elderly to
               allow a true “no touch aortic technique” where there is robust evidence for a reduction in the risk of most
                                                       [22]
               major complications and, in particular, stroke . There is evidence from RCTs that TAR with composite
               grafts is a safe and useful procedure in the elderly [23-25] .


               Long-term outcomes
               The added value of TAR in CABG becomes particularly apparent when assessing long-term results.
                          [26]
               Tavilla et al.  recently reported 20-year outcomes of TAR using BIMA and gastroepiploic artery as
               in situ grafts in patients with 3-vessel disease. The Kaplan-Meier estimated survival probabilities were
               73.9% (95%CI: 67.2%-79.5%) and 63.5% (95%CI: 55.7%-70.4%) for overall survival and 57.9% (95%CI: 50.7%-
               64.5%) and 47.9% (95%CI: 40.1%-55.3%) for freedom from major adverse cardiac events at 15 and 20 years
               respectively. The respective estimated cumulative incidences at 15 and 20 years were 7.0% (95%CI: 3.5%-
               10.6%) and 7.8% 95%CI: 4.0%-11.6%) for myocardial infarction, 8.6% (95%CI: 4.7%-12.5%) and 9.3% (95%CI:
               5.2%-13.3%) for percutaneous reintervention, 7.0% (95%CI: 3.5%-10.5%) and 7.0% (95%CI: 3.5%-10.5%) for
   213   214   215   216   217   218   219   220   221   222   223